Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedAug 01, 2026
DataAggregated Company Financials
Companies51
  • 7D-0.9%
  • 3M-8.6%
  • 1Y21.0%
  • YTD-7.4%

In the last week, the Pharma industry is flat overall, with Curaleaf Holdings standing out by going down 4.2%. The past year has been better, since the industry has gained 21% in that time. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 02 Aug 2026CA$13.1bCA$10.6b-CA$1,716,249,606.259.9x-7.6x1.2x
Tue, 30 Jun 2026CA$14.0bCA$10.7b-CA$1,736,735,384.648.5x-8.1x1.3x
Thu, 28 May 2026CA$16.1bCA$12.2b-CA$1,894,257,182.778.1x-8.5x1.3x
Sat, 25 Apr 2026CA$15.8bCA$11.2b-CA$1,666,746,960.2314.8x-9.5x1.4x
Mon, 23 Mar 2026CA$13.2bCA$11.3b-CA$1,701,194,077.0211.5x-7.7x1.2x
Wed, 18 Feb 2026CA$14.3bCA$11.2b-CA$1,898,020,108.9314.9x-7.5x1.3x
Fri, 16 Jan 2026CA$17.0bCA$11.3b-CA$1,959,031,887.0516.3x-8.7x1.5x
Sun, 14 Dec 2025CA$19.2bCA$11.2b-CA$1,911,998,737.3214.8x-10x1.7x
Tue, 11 Nov 2025CA$15.2bCA$11.3b-CA$1,876,410,918.5517.8x-8.1x1.4x
Thu, 09 Oct 2025CA$18.4bCA$11.2b-CA$2,036,511,751.4235.8x-9x1.6x
Sat, 06 Sep 2025CA$15.9bCA$11.2b-CA$2,031,100,344.4338.1x-7.8x1.4x
Mon, 04 Aug 2025CA$11.8bCA$11.8b-CA$2,580,662,352.2716.7x-4.6x1x
Wed, 02 Jul 2025CA$9.7bCA$11.7b-CA$2,515,850,664.9517x-3.8x0.8x
Fri, 30 May 2025CA$23.2bCA$11.8b-CA$2,396,620,795.0717.5x-9.7x2x
Sun, 27 Apr 2025CA$10.5bCA$11.9b-CA$2,537,137,906.5420.2x-4.1x0.9x
Tue, 25 Mar 2025CA$10.5bCA$12.3b-CA$2,567,787,653.6519.9x-4.1x0.9x
Thu, 20 Feb 2025CA$12.3bCA$12.1b-CA$2,212,835,656.1422.9x-5.5x1x
Sat, 18 Jan 2025CA$12.2bCA$12.2b-CA$2,421,943,229.6529.8x-5x1x
Mon, 16 Dec 2024CA$12.7bCA$12.0b-CA$2,588,051,717.1821.9x-4.9x1.1x
Wed, 13 Nov 2024CA$13.0bCA$11.9b-CA$2,631,380,295.5615.1x-4.9x1.1x
Fri, 11 Oct 2024CA$18.3bCA$11.7b-CA$2,697,603,068.9017.2x-6.8x1.6x
Sun, 08 Sep 2024CA$17.1bCA$11.6b-CA$2,699,993,509.6420x-6.4x1.5x
Tue, 06 Aug 2024CA$18.8bCA$11.7b-CA$3,096,658,580.3919.3x-6.1x1.6x
Thu, 04 Jul 2024CA$18.8bCA$11.7b-CA$3,225,203,624.5719.2x-5.8x1.6x
Sat, 01 Jun 2024CA$21.1bCA$11.9b-CA$3,474,747,660.6412.8x-6.1x1.8x
Mon, 29 Apr 2024CA$22.9bCA$11.8b-CA$3,444,223,192.038.4x-6.7x1.9x
Wed, 27 Mar 2024CA$23.2bCA$11.9b-CA$3,504,102,648.099.3x-6.6x2x
Fri, 23 Feb 2024CA$21.8bCA$12.0b-CA$4,642,695,320.799.4x-4.7x1.8x
Sun, 21 Jan 2024CA$20.4bCA$12.3b-CA$6,754,384,129.009.6x-3x1.6x
Tue, 19 Dec 2023CA$17.6bCA$12.3b-CA$6,738,434,260.008.2x-2.6x1.4x
Thu, 16 Nov 2023CA$17.5bCA$12.4b-CA$6,689,449,134.008.6x-2.6x1.4x
Sat, 14 Oct 2023CA$18.3bCA$12.4b-CA$7,333,238,247.0013.2x-2.5x1.5x
Mon, 11 Sep 2023CA$20.7bCA$13.0b-CA$7,922,680,059.0015.2x-2.6x1.6x
Wed, 09 Aug 2023CA$15.1bCA$13.3b-CA$9,749,939,151.0012x-1.5x1.1x
Price to Earnings Ratio

-1.5x


Total Market Cap: CA$15.1bTotal Earnings: -CA$9,749,939,151.00Total Revenue: CA$13.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Canadian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 1.4x is higher than the industry's current PS ratio of 1.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 7.3% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-0.33%
Healthcare-1.24%
Pharma-0.92%
Pharma-0.92%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
APTX Apotex HealthCA$36.601.8%
+CA$150.8m		n/aPE22.4x
GTII Green Thumb IndustriesCA$10.092.0%
+CA$43.8m		8.3%PE13x
CPH Cipher PharmaceuticalsCA$16.833.6%
+CA$14.7m		38.3%PE9.9x
GUD Knight TherapeuticsCA$9.841.1%
+CA$10.8m		59.5%PE172.2x
CRDL Cardiol TherapeuticsCA$1.765.4%
+CA$10.4m		-7.9%PB8.4x

Latest News

CPH
CA$16.83
Cipher Pharmaceuticals
7D
3.6%
1Y
38.3%
VREO
CA$13.20
Vireo Growth
7D
-3.6%
1Y
-42.1%
GUD
CA$9.84
Knight Therapeutics
7D
1.1%
1Y
59.5%
XLY
CA$2.62
Auxly Cannabis Group
7D
4.0%
1Y
38.6%
GRIN
CA$0.58
Grown Rogue International
7D
5.5%
1Y
7.4%
TSND
CA$0.70
TerrAscend
7D
-5.4%
1Y
12.9%
WEED
CA$1.29
Canopy Growth
7D
1.6%
1Y
-11.6%
CURA
CA$12.41
Curaleaf Holdings
7D
-4.2%
1Y
111.1%
Narrative Update • Jul 23

CURA: International Supply Deals And Spain Approval Will Support Future Upside Potential

Analysts have raised their CA$ price target on Curaleaf Holdings by CA$1, citing updated assumptions for fair value, revenue growth, profit margins and future P/E multiples that, in their view, better reflect the company’s outlook. What’s in the News for Curaleaf Holdings Curaleaf International Limited entered a long term international supply agreement with Cannara Biotech Inc.
NVRS
CA$1.06
Noveris Health Sciences
7D
-17.2%
1Y
112.0%
HITI
CA$2.97
High Tide
7D
-2.6%
1Y
-1.0%
APTX
CA$36.60
Apotex Health
7D
1.8%
1Y
n/a
CRON
CA$3.95
Cronos Group
7D
-0.5%
1Y
46.8%
CL
CA$0.90
Cresco Labs
7D
-6.3%
1Y
4.7%
GTII
CA$10.09
Green Thumb Industries
7D
2.0%
1Y
8.3%
Narrative Update • Jul 09

GTII: Partial Rescheduling Order Will Support Future Upside In Key Markets

Analysts have raised their CA$ fair value estimate for Green Thumb Industries from CA$17.30 to CA$18.45, citing updated assumptions around discount rates, profit margins, and a higher future P/E multiple following recent sector commentary on cannabis rescheduling and company-specific research. Analyst Commentary Recent Street research on Green Thumb Industries has highlighted both supportive and cautious views around the stock's valuation, particularly in light of sector commentary on cannabis rescheduling.
ALGO
CA$0.18
Light AI
7D
-17.8%
1Y
-7.5%
CRDL
CA$1.76
Cardiol Therapeutics
7D
5.4%
1Y
-7.9%
Analysis Article • Jun 04

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...